The PTEN-AKT3 Signaling Cascade As a Therapeutic Target in Melanoma

Overview

Journal Pigment Cell Melanoma Res

Date 2009 Jun 5

PMID 19493313

Citations 73

Authors

SubbaRao V Madhunapantula

Gavin P Robertson

Affiliations

Soon will be listed here.

Abstract

Melanocytes undergo extensive genetic changes during transformation into aggressive melanomas. These changes deregulate genes whose aberrant activity promotes the development of this disease. The phosphoinositide-3-kinase (PI3K) and mitogen-activated protein (MAP) kinase pathways are two key signaling cascades that have been found to play prominent roles in melanoma development. These pathways relay extra-cellular signals via an ordered series of consecutive phosphorylation events from cell surface throughout the cytoplasm and nucleus regulating diverse cellular processes including proliferation, survival, invasion and angiogenesis. It is generally accepted that therapeutic agents would need to target these two pathways to be an effective therapy for the long-term treatment of advanced-stage melanoma patients. This review provides an overview of the PI3 kinase pathway focusing specifically on two members of the pathway, called PTEN and Akt3, which play important roles in melanoma development. Mechanisms leading to deregulation of these two proteins and therapeutic implications of targeting this signaling cascade to treat melanoma are detailed in this review.

Citing Articles

Deep learning prioritizes cancer mutations that alter protein nucleocytoplasmic shuttling to drive tumorigenesis.

Zheng Y, Yu K, Lin J, Liang Z, Zhang Q, Li J Nat Commun. 2025; 16(1):2511.

PMID: 40087285 DOI: 10.1038/s41467-025-57858-8.

Establishment of Novel High-Grade Serous Ovarian Carcinoma Cell Line OVAR79.

Shnaider P, Malyants I, Ivanova O, Gordeeva V, Svirina E, Zakharzhevskaya N Int J Mol Sci. 2025; 25(24.

PMID: 39769003 PMC: 11676670. DOI: 10.3390/ijms252413236.

miRNAs Involvement in Modulating Signalling Pathways Involved in Ros-Mediated Oxidative Stress in Melanoma.

Escobar Moreno J, Fajardo Castiblanco J, Riano Rodriguez L, Barrios Ospina P, Zabala Bello C, Munoz Roa E Antioxidants (Basel). 2024; 13(11).

PMID: 39594467 PMC: 11591318. DOI: 10.3390/antiox13111326.

BRAF inhibitor candidate molecule usnic acid might use both intrinsic and extrinsic pathways of apoptosis.

Buyuk B, Cansaran Duman D, Duman T Turk J Med Sci. 2024; 54(5):1116-1126.

PMID: 39473730 PMC: 11518357. DOI: 10.55730/1300-0144.5890.

CD133-Dependent Activation of Phosphoinositide 3-Kinase /AKT/Mammalian Target of Rapamycin Signaling in Melanoma Progression and Drug Resistance.

Kharouf N, Flanagan T, Alamodi A, Al Hmada Y, Hassan S, Shalaby H Cells. 2024; 13(3.

PMID: 38334632 PMC: 10854812. DOI: 10.3390/cells13030240.

References

Staal S . Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci U S A. 1987; 84(14):5034-7. PMC: 305241. DOI: 10.1073/pnas.84.14.5034. View

Chan T, Tsichlis P . PDK2: a complex tail in one Akt. Sci STKE. 2001; 2001(66):pe1. DOI: 10.1126/stke.2001.66.pe1. View

Al-Khouri A, Ma Y, Togo S, Williams S, Mustelin T . Cooperative phosphorylation of the tumor suppressor phosphatase and tensin homologue (PTEN) by casein kinases and glycogen synthase kinase 3beta. J Biol Chem. 2005; 280(42):35195-202. DOI: 10.1074/jbc.M503045200. View

Yin Y, Shen W . PTEN: a new guardian of the genome. Oncogene. 2008; 27(41):5443-53. DOI: 10.1038/onc.2008.241. View

Stewart A, Mhashilkar A, Yang X, Ekmekcioglu S, Saito Y, Sieger K . PI3 kinase blockade by Ad-PTEN inhibits invasion and induces apoptosis in RGP and metastatic melanoma cells. Mol Med. 2002; 8(8):451-61. PMC: 2040008. View

Huang J, Manning B . A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans. 2009; 37(Pt 1):217-22. PMC: 2778026. DOI: 10.1042/BST0370217. View

Bellacosa A, De Feo D, Godwin A, BELL D, Cheng J, Altomare D . Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer. 1995; 64(4):280-5. DOI: 10.1002/ijc.2910640412. View

Ferguson K, Kavran J, Sankaran V, Fournier E, Isakoff S, Skolnik E . Structural basis for discrimination of 3-phosphoinositides by pleckstrin homology domains. Mol Cell. 2000; 6(2):373-84. DOI: 10.1016/s1097-2765(00)00037-x. View

Marone R, Erhart D, Mertz A, Bohnacker T, Schnell C, Cmiljanovic V . Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors. Mol Cancer Res. 2009; 7(4):601-13. DOI: 10.1158/1541-7786.MCR-08-0366. View

10.

Bedogni B, Welford S, Kwan A, Ranger-Moore J, Saboda K, Powell M . Inhibition of phosphatidylinositol-3-kinase and mitogen-activated protein kinase kinase 1/2 prevents melanoma development and promotes melanoma regression in the transgenic TPRas mouse model. Mol Cancer Ther. 2006; 5(12):3071-7. DOI: 10.1158/1535-7163.MCT-06-0269. View

11.

Shayesteh L, Lu Y, Kuo W, Baldocchi R, Godfrey T, Collins C . PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet. 1999; 21(1):99-102. DOI: 10.1038/5042. View

12.

Burgering B, Coffer P . Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature. 1995; 376(6541):599-602. DOI: 10.1038/376599a0. View

13.

Thompson F, Emerson J, Olson S, Weinstein R, Leavitt S, Leong S . Cytogenetics of 158 patients with regional or disseminated melanoma. Subset analysis of near-diploid and simple karyotypes. Cancer Genet Cytogenet. 1995; 83(2):93-104. DOI: 10.1016/0165-4608(95)00057-v. View

14.

Robertson G, Herbst R, Nagane M, Huang H, Cavenee W . The chromosome 10 monosomy common in human melanomas results from loss of two separate tumor suppressor loci. Cancer Res. 1999; 59(15):3596-601. View

15.

Zhao Y, Zhang Y, Yang Z, Li A, Dong J . Simultaneous knockdown of BRAF and expression of INK4A in melanoma cells leads to potent growth inhibition and apoptosis. Biochem Biophys Res Commun. 2008; 370(3):509-13. DOI: 10.1016/j.bbrc.2008.03.148. View

16.

Dey A, Wong E, Kua N, Teo H, Tergaonkar V, Lane D . Hexamethylene bisacetamide (HMBA) simultaneously targets AKT and MAPK pathway and represses NF kappaB activity: implications for cancer therapy. Cell Cycle. 2008; 7(23):3759-67. DOI: 10.4161/cc.7.23.7213. View

17.

Wang Y, Lee C . MicroRNA and cancer--focus on apoptosis. J Cell Mol Med. 2009; 13(1):12-23. PMC: 3823033. DOI: 10.1111/j.1582-4934.2008.00510.x. View

18.

Cheng J, Godwin A, Bellacosa A, Taguchi T, Franke T, Hamilton T . AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci U S A. 1992; 89(19):9267-71. PMC: 50107. DOI: 10.1073/pnas.89.19.9267. View

19.

Yang H, Kong W, He L, Zhao J, ODonnell J, Wang J . MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008; 68(2):425-33. DOI: 10.1158/0008-5472.CAN-07-2488. View

20.

Bastian B, Leboit P, Hamm H, Brocker E, Pinkel D . Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res. 1998; 58(10):2170-5. View